ANAB — AnaptysBio Inc. stock price and chart

Share this page

ANAB

$46.61-4.31%

as of close, Oct 16, 2026

☾ AH $46.61 -4.31%

AnaptysBio Inc.Stock · HealthcareRussell 2000 0.04%Nasdaq Composite 0.004%Russell 3000 0.003%US Stock Market 0.002%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEESEE

20172019202120242026

10.020.030.040.050.060.070.080.0020.0M$46.61

2026-10-16

Price$46.61

MA20$54.92

MA50$45.25

Vol2.1M

What would $1,000 invested in ANAB be worth today? →

ANAB returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $46.61
YTD price return: +44.21%
YTD total return: +44.21%
Next earnings: Nov 3, 2026
Market cap: 1.4B2017-03 375M2026-10 1.4B+271.4% over the window
Enterprise value: 1.3B
Shares outstanding: 29.9M2016-06 3.5M2026-06 29.9M+754.6% over the window
52W low: $20.18
52W high: $72.36
From 52W high: -35.59%
From 52W low: +130.97%
52W range: 51%

Volume

Rel volume: 0.73×
30D volume: 568.7K
30D $ vol: 29.1M

Fundamentals

Sales (ttm): 232.4M2016-12 16.7M2026-03 232.4M+1292.9% over the window
Sales/share: $7.772016-12 $6.292026-03 $7.99+26.9% over the window
EPS (ttm): -$0.902016-12 -$1.622026-03 -$0.89-45.0% over the window
FCF (ttm): 4.4M2016-12 -9.1M2026-03 4.4M-148.6% over the window
FCF/share: $0.152016-12 -$3.432026-03 $0.15-104.4% over the window
Book value/share: $0.352016-12 -$14.432026-06 $0.35-102.5% over the window
Net margin: -11.53%2016-12 -25.5%2026-03 -11.5%-54.8% over the window
ROE: -253.07%2017-03 -13.4%2026-03 -210.1%+1462.9% over the window
ROA: -8.45%2016-12 -6.8%2026-03 -8.1%+18.6% over the window
Current ratio: 5.612016-12 10.202026-06 5.61-45.0% over the window

Growth (CAGR, ttm) · 10Y

Sales: +107.83%2025-03-31 → 2026-03-31111.9M → 232.4M (+107.7% total)+179.02%2023-03-31 → 2026-03-3110.7M → 232.4M (+2073.7% total)+26.68%2021-03-31 → 2026-03-3171.2M → 232.4M (+226.2% total)+28.66%2015-12-31 → 2026-03-3117.6M → 232.4M (+1222.6% total)
Shares: +6.79%2025-06-30 → 2026-06-3028M → 29.9M (+6.8% total)+4.04%2023-06-30 → 2026-06-3026.5M → 29.9M (+12.6% total)+1.73%2021-06-30 → 2026-06-3027.4M → 29.9M (+9.0% total)+23.93%2016-06-30 → 2026-06-303.5M → 29.9M (+754.6% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +109.83%2025-03-31 → 2026-03-31$3.81 → $7.99 (+109.7% total)+170.40%2023-03-31 → 2026-03-31$0.40 → $7.99 (+1878.5% total)+25.13%2021-03-31 → 2026-03-31$2.60 → $7.99 (+206.8% total)+4.63%2015-12-31 → 2026-03-31$5.02 → $7.99 (+59.0% total)
Book value/share: n/a-60.14%2023-06-30 → 2026-06-30$5.59 → $0.35 (-93.7% total)-52.12%2021-06-30 → 2026-06-30$14.06 → $0.35 (-97.5% total)n/a
Price: +103.34%2025-10-16 → 2026-10-16$22.93 → $46.61 (+103.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+55.69%2023-10-16 → 2026-10-16$12.35 → $46.61 (+277.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+19.51%2021-10-15 → 2026-10-16$19.11 → $46.61 (+143.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+15.66%2017-01-26 → 2026-10-16$11.33 → $46.61 (+311.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +103.34%2025-10-16 → 2026-10-16$22.93 → $46.61 (+103.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+55.69%2023-10-16 → 2026-10-16$12.35 → $46.61 (+277.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+19.51%2021-10-15 → 2026-10-16$19.11 → $46.61 (+143.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.66%2017-01-26 → 2026-10-16$11.33 → $46.61 (+311.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -52.0×2017-03 -25.332026-10 -51.98+105.3% over the window
Fwd P/E: 9.1×
P/S (ttm)Market cap ÷ TTM revenue.: 6.0×2017-03 31.732026-10 5.99-81.1% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 131.6×2017-03 3.412026-10 131.56+3763.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 316.0×2017-03 -24.722026-10 315.84-1377.8% over the window
EV/EBITDA (fy): 5.8×
EV/Sales (ttm): 5.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 0.32%2016-12 -2.4%2026-03 0.4%-116.9% over the window
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($36.2M) ÷ today's market cap ($1.4B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.60%2016-12 0.0%2026-03 3.4%+1261854.7% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $36.2M + TTM dividends $0) ÷ today's market cap ($1.4B). Same caveat as the cash buyback yield.: 2.60%2016-12 0.0%2026-03 3.4%+1261854.7% over the window

Vs own 10Y history

P/S: 23rd
P/B: 96th

Bar = where today’s multiple sits in ANAB’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-4.31%

+1.44%

-14.18%

-13.92%

YTD

+44.21%

+103.24%

+143.86%

Financial statements

Open full ANAB financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

ANAB — AnaptysBio Inc. price, chart and key statistics